Literature DB >> 32072428

LNCRNA OIP5-AS1 regulates oxidative low-density lipoprotein-mediated endothelial cell injury via miR-320a/LOX1 axis.

Chunmei Zhang1, Hailing Yang2, Yan Li2, Pengfei Huo1, Piyong Ma3.   

Abstract

An increasing amount of research showed that endothelial cells (ECs) play crucial role in vascular disorders such as atherosclerosis (AS). LncRNA OIP5-AS1 and microRNA-320a (miR-320a) were reported to exert function in ECs. The purpose of this research was to investigate the functional mechanism of OIP5-AS1 and miR-320a in ox-LDL-treated HUVECs. The RNA levels of OIP5-AS1, miR-320a, and Lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The protein levels of LOX1 and cell apoptosis-related genes were determined by Western blot assay. In addition, Cell Counting Kit-8 (CCK-8) and flow cytometry analysis were used to assess cell viability and apoptosis, respectively. Lactate dehydrogenase (LDH) activity was measured using LDH release assay. Besides, the interaction between miR-320a and OIP5-AS1 or LOX1 was predicted by starbase and verified by the dual-luciferase reporter assay. OIP5-AS1 expression was increased and miR-320a expression was decreased in oxidative low-density lipoprotein (ox-LDL)-treated HUVECs. OIP5-AS1 knockdown upregulated ox-LDL-treated HUVECs viability and suppressed apoptosis as well as LDH release. Interestingly, OIP5-AS1 elevated LOX1 level through downregulating miR-320a expression. As expected, miR-320a modulated LOX1 expression to mediate ox-LDL-treated HUVECs progression. Furthermore, OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs. Our results demonstrated that the depletion of OIP5-AS1 enhanced cell viability and repressed apoptosis as well as LDH release in ox-LDL-treated HUVECs, providing potential target for the treatment of AS.

Entities:  

Keywords:  Atherosclerosis; LOX1; LncRNA OIP5-AS1; Proliferation; miR-320a; ox-LDL

Year:  2020        PMID: 32072428     DOI: 10.1007/s11010-020-03688-9

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  8 in total

Review 1.  The role of lncRNA OIP5-AS1 in cancer development and progression.

Authors:  Cheng Zheng; Man Chu; Qiuli Chen; Cheng Chen; Zhi-Wei Wang; Xiao Chen
Journal:  Apoptosis       Date:  2022-03-22       Impact factor: 4.677

2.  Exosomes released from mesenchymal stem cells overexpressing microRNA-30e ameliorate heart failure in rats with myocardial infarction.

Authors:  Lianmei Pu; Xiangyun Kong; Hong Li; Xue He
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 3.  Macrophage Long Non-Coding RNAs in Pathogenesis of Cardiovascular Disease.

Authors:  Marcin Wysoczynski; Jae Kim; Joseph B Moore; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2020-07-11

Review 4.  The mechanisms of glycolipid metabolism disorder on vascular injury in type 2 diabetes.

Authors:  Xiatian Chen; Chengzhen Shi; Yin Wang; Hua Yu; Yu Zhang; Jiaxuan Zhang; Peifeng Li; Jinning Gao
Journal:  Front Physiol       Date:  2022-08-31       Impact factor: 4.755

5.  Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.

Authors:  Li Kong; Yang Sun; Maosheng Chen; Yan Dai; Zhen Liu
Journal:  Exp Ther Med       Date:  2020-08-25       Impact factor: 2.447

Review 6.  LncRNAs Stand as Potent Biomarkers and Therapeutic Targets for Stroke.

Authors:  Junfen Fan; Madeline Saft; Nadia Sadanandan; Bella Gonzales-Portillo; You Jeong Park; Paul R Sanberg; Cesario V Borlongan; Yumin Luo
Journal:  Front Aging Neurosci       Date:  2020-10-19       Impact factor: 5.750

Review 7.  Long non-coding RNA OIP5-AS1 (Cyrano): A context-specific regulator of normal and disease processes.

Authors:  Serena Wooten; Keriayn N Smith
Journal:  Clin Transl Med       Date:  2022-01

8.  LncRNA OIP5-AS1 accelerates intervertebral disc degeneration by targeting miR-25-3p.

Authors:  Zhaoping Che; Jie Xueqin; Zongyu Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.